Avanos Medical has divested its Hyaluronic Acid (HA) product line to Channel-Markers Medical (CMM), a privately-held company based in Raleigh, N.C.

The divested portfolio includes TriVisc and GenVisc 850 products, which are used to treat osteoarthritis (OA) pain in the knee. The injectable HA therapies are engineered to help OA patients manage symptoms and improve joint function.

Avanos said the transaction aligns with its ongoing transformation focused on advancing its Pain Management & Recovery and Specialty Nutrition Systems segments.

“This divestiture represents a meaningful step in advancing our transformation strategy and reinforcing our commitment to focused growth,” said Dave Pacitti, Avanos’ CEO. “By aligning our product portfolio more closely with our strategic priorities, we expect to strengthen our ability to invest in those areas where we see the greatest potential to lead, innovate, and deliver long-term value for patients, customers, and shareholders.”

Channel-Markers Medical specializes in development and commercialization of joint health, regenerative therapies, and minimally invasive pain management solutions. Acquiring the HA portfolio supports its goal of bolstering its presence in musculoskeletal health and injectable pain therapies.

Avanos will provide transition support through the end of the year to ensure uninterrupted service and support.

“This acquisition aligns with our mission to deliver high-quality, clinically proven therapies that improve patient mobility and quality of life,” said David Toledo, one of CMM’s managing partners. “We’re proud to integrate these trusted brands into our portfolio as we accelerate our growth in the pain therapy market.”